

Message

From: Hines, Ronald [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=464F333922CC4AA68DB2A1677122AB58-HINES, RONALD]
Sent: 11/8/2018 2:11:35 AM
To: Gillespie, Andrew [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=dce99ece87694a06b3009d7756e2a89e-Gillespie, Andrew]
Subject: Re: Nafion Byproduct 2 Briefing

Ex. 5 Deliberative Process (DP)

I will get a better picture of what those are and distribute. They are planning a publication.

Ron Hines, PhD, ATS
Associate Director for Health
US/EPA/ORD NHEERL

Sent from my iPhone

On Nov 7, 2018, at 20:45, Gillespie, Andrew <Gillespie.Andrew@epa.gov> wrote:

Thanks Ron, I appreciate that you are always meticulous in sharing what you know in a timely manner.

Ex. 5 Deliberative Process (DP)

Where do you see this new NHEERL effort going? Is this sufficient to result in a pub, or are we still in scoping and exploratory stage?

Andrew J. R. Gillespie, Ph. D.
Associate Director, US EPA/ORD/NERL
ORD Executive Lead for PFAS R&D

Office 919 541 3655 Cell: Ex. 6 Personal Privacy (PP)

From: Hines, Ronald
Sent: Wednesday, November 07, 2018 1:55 PM
To: Gillespie, Andrew <Gillespie.Andrew@epa.gov>
Subject: Re: Nafion Byproduct 2 Briefing

Andy,

I did mention it at one of our update meetings.

Ex. 5 Deliberative Process (DP)

Ex. 5 Deliberative Process (DP) That has not started and I was waiting to be briefed before I sent you any more detail. Ex. 5 Deliberative Process (DP)

Ex. 5 Deliberative Process (DP)

Ron Hines, PhD, ATS
Associate Director for Health
US/EPA/ORD NHEERL

Sent from my iPhone

On Nov 7, 2018, at 13:05, Gillespie, Andrew <Gillespie.Andrew@epa.gov> wrote:

Hi Ron – were you aware this work was ongoing? I don't recall hearing about it, but would not be surprised if you had shared it with me and I just didn't internalize it.

Thanks, Andy

Andrew J. R. Gillespie, Ph. D.
Associate Director, US EPA/ORD/NERL
ORD Executive Lead for PFAS R&D

Office 919 541 3655 Cel Ex. 6 Personal Privacy (PP)

From: Hines, Ronald

Sent: Wednesday, November 07, 2018 12:57 PM

To: Rodan, Bruce <rodan.bruce@epa.gov>; Gillespie, Andrew

<Gillespie.Andrew@epa.gov>; Jones, Samantha <Jones.Samantha@epa.gov>; Sams, Reeder <Sams.Reeder@epa.gov>

Cc: Chernoff, Neil <Chernoff.Neil@epa.gov>; Hill, Donna <Hill.Donna@epa.gov>; Lang, Johnsie <lang.johnsie@epa.gov>; Lindstrom, Andrew <Lindstrom.Andrew@epa.gov>; Strynar, Mark <Strynar.Mark@epa.gov>; Rogers, John M. <Rogers.John@epa.gov>; Lau, Chris <Lau.Christopher@epa.gov>; Russo, Bill <Russo.Bill@epa.gov>; Holt, Kay <Holt.Kay@epa.gov>; Cascio, Wayne <Cascio.Wayne@epa.gov>; Guiseppi-Elie, Annette <Guiseppi-Elie.Annette@epa.gov>; Watkins, Tim <Watkins.Tim@epa.gov>; Jones, Marjorie <Jones.Marjorie@epa.gov>; Smith, Emily J. <Smith.Emily@epa.gov>
Subject: Nafion Byproduct 2 Briefing

Good morning,

In the interest of transparency and no surprises, I have attached a summary of a briefing I received this morning from Neil Chernoff, Donna Hill, Johnsie Lang (NHEERL) and Mark Strynar (NERL) regarding Nafion Byproduct 2 (NBP2). Ex. 5 Deliberative Process (DP)

Ex. 5 Deliberative Process (DP)

Ex. 5 Deliberative Process (DP) NERL has been collaborating on that study and Emily Smith is coordinating communication with EPA.

The briefing attached provides results on some initial toxicity testing done with NBP2.

I will be on travel starting in 10 min, but will have my phone with me. Also, John Rogers will be acting for me, was at the briefing, and can field any questions.

Ron Hines, PhD
Associate Director for Health
US EPA, NHEERL
109 T.W. Alexander Dr., MD 305-02
Research Triangle Park, NC 27711
Tel: 919 541-5622

Cell: Ex. 6 Personal Privacy (PP)